🔎 Trials Near Me

መነሻ › የጡንቻ ካንሰር › ሚሺጋን

በሚሺጋን ለየጡንቻ ካንሰር የሚደረጉ ክሊኒካዊ ጥናቶች

ለየጡንቻ ካንሰር የሚደረጉ 74 ጥናቶች በሚሺጋን ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በሚሺጋን ውስጥ ያሉ ከተሞች

Official study text (English)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • እና 68 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06760819

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

  • Henry Ford Hospital, Detroit
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT07102381

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • University of Michigan, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT06324357

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

  • McLaren Proton Therapy Center, Flint
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 50 እና ከዚያ በላይ · ሴቶች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT01766297

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  • Henry Ford Health ( Site 0002), Detroit
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06312176

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  • Research Site, Detroit
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06103864

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  • University of Michigan Rogel Cancer Center, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07007559

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  • Clinical Trial Site, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  • Karmanos Cancer Center - Wayne State University, Detroit
  • Cancer & Hematology Centers, Grand Rapids
  • Munson Medical Center Cowell Family Cancer Center, Traverse City
ተሳታዮችን በመፈለግ ላይ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT07214532

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • Barbara Ann Karmanos Cancer Institute, Detroit
  • BAMF Health Inc., Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • Barbara Ann Karmanos Cancer Institute, Detroit
  • BAMF Health Inc., Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07213791

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  • Henry Ford Hospital, Detroit
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT05894239

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  • Karmanos Cancer Center, Detroit
  • Profound Research LLC at Michigan Hematology and Oncology Consultants, Royal Oak
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07173751

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

  • Karmanos Cancer Institute, Detroit
  • Brigitte Harris Cancer Pavilion BHCP, Detroit
  • START Midwest, LLC, Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT06827236

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  • The Cancer & Hematology Centers, Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ሴፕቴ 2026 · NCT06492616

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

  • Cancer and Leukemia Center, Sterling Heights
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሴቶች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT07541079

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Karmanos Cancer Institiute, Detroit
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ሴፕቴ 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • University of Michigan, Ann Arbor
  • Henry Ford Cancer Institute, Detroit
  • START - Midwest Cancer Research Center, Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT06253871

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • Henry Ford Hospital, Detroit
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT05386108

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

  • Profound Research LLC at Michigan Hematology and Oncology Consultants, Royal Oak
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ18 እስከ 55 · ሴቶች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT07310420

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT06400472

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

  • Wayne State University - Barbara Ann Karmanos Cancer Institute, Detroit
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT07287917

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  • University of Michigan, Ann Arbor
  • Profound Research LLC, Royal Oak
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT06982521

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

  • Trinity Health, Ann Arbor
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ18 እስከ 99 · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT07211178

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

  • Trinity Health IHA - Obstetrics and Gynecology West Arbor, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 22 እና ከዚያ በላይ · ሴቶች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT05379153

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  • Henry Ford Health System, Detroit
  • Cancer & Hematology Centers of Western Michigan, Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT06790693

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Henry Ford Cancer Institute-Downriver, Brownstown
  • Henry Ford Health Center - Brownstown, Brownstown
  • Henry Ford Health Center - Chesterfield, Chesterfield
  • እና 13 ተጨማሪ
ተሳታዮችን በመፈለግ ላይጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ45 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT06995898

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • እና 73 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 60 · ሴቶች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT05879926

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  • South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT07029399

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

  • Karmanos Cancer Institute at McLaren Bay Region, Bay City
  • Karmanos Cancer Institute at McLaren Clarkston, Clarkston
  • Karmanos Cancer Institute, Detroit
  • እና 5 ተጨማሪ
ተሳታዮችን በመፈለግ ላይ
እድሜ 22 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ26 ኦገስ 2026 · NCT07227831

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  • Wayne State University/Karmanos Cancer Institute, Detroit
  • Weisberg Cancer Treatment Center, Farmington Hills
  • McLaren Cancer Institute-Flint, Flint
  • እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT06500481

A Study of MGC026 in Participants With Advanced Solid Tumors

  • START Midwest, Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ኦገስ 2026 · NCT06242470

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  • Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ኦገስ 2026 · NCT06926868

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

  • University of Michigan Rogel Cancer Center, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 2ጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ45 እስከ 74 · ሴቶች · የተሻሻለው በ4 ኦገስ 2026 · NCT06195306

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Karmanos Cancer Institute, Detroit
  • START Midwest, Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ኦገስ 2026 · NCT05579366

E-Mindfulness Approaches for Living After Breast Cancer

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • እና 20 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 50 · ሁሉም ጾታዎች · የተሻሻለው በ4 ኦገስ 2026 · NCT06748222

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

  • Henry Ford Health, Detroit
ተሳታዮችን በመፈለግ ላይጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ45 እስከ 74 · ሴቶች · የተሻሻለው በ31 ጁላይ 2026 · NCT05625659

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

  • BAMF Health, Grand Rapids
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ18 እስከ 100 · ሁሉም ጾታዎች · የተሻሻለው በ29 ጁላይ 2026 · NCT06562192

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

  • University of Michigan Rogel Cancer Center, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 55 · ሴቶች · የተሻሻለው በ27 ጁላይ 2026 · NCT06184750

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።